On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
Exploring the companies and themes that make up this emerging and exciting new sector
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
The next big trend in mental health treatments? Psychedelic therapy.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
Value, Growth and Opportunity: Why Psychedelic Stocks Are Poised To Rebound In 2022
After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.
Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy
Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.
The Military Mental Health Crisis, A National Tragedy: Part III
The Military Mental Health Crisis affects over 1 million veterans and has claimed 115,000+ lives in the past 20 years. Fortunately, there is finally hope.
Ketamine therapy can reduce depression symptoms and suicidal thoughts: review
A systematic review of dozens of research papers has found that ketamine therapy has a quick, short-term effect of reducing depression symptoms and suicidal thoughts, making it a promising mental health treatment alternative.
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
MindMed announces that the FDA has placed "clinical hold" on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).
Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics
Novamind announces a definitive agreement to acquire Arizona-based Foundations for Change, PLC.
The Military Mental Health Crisis, A National Tragedy: Part II
In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
Cybin Provides 2021 Year End Summary
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.